Browsing Tag
Lupuzor
2 posts
ImmuPharma (LSE: IMM) has two biotech catalysts, but can P140 finally deliver the deal?
ImmuPharma targets a P140 licensing deal while LSE trades below its Lanstead benchmark. The next partner decision could reshape the biotech story.
ImmuPharma at 4p is a P140 licensing bet: What IMM retail investors should know
ImmuPharma targets a P140 licensing deal in 2026 with cash to H2 2028. Here is what IMM retail investors need to weigh before chasing the small-cap biotech.